Is there a pharmacokinetic case for moving liraglutide injection day by forty-two days?

The specifics, since they change the answer: liraglutide · forty-two days.

I would like the mechanism, because I want to be able to reason about the cases nobody has written about.

I have tried to reason it out from first principles and got to two contradictory conclusions.

What is actually going on here, physically?

The titration schedule is a tolerability instrument, not an efficacy one. Nothing in the ladder is there to make the compound work better; every step exists to make the gastrointestinal adverse-event curve survivable.

Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.

The relevant detail is that missing a dose by three days on a weekly schedule takes the trough down by less than a factor of 1.35, which is well inside the variation you would see between two on-time weeks. Missing it by five or more days is where the label instructions start to differ between agents, and the reason is how close the next scheduled dose is rather than any mechanistic threshold.

Worth noting that inter-individual variability in exposure at a given dose is substantial, which is why the ladder exists rather than a single population dose.

Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.

The steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.

Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.

It helps to be literal here: holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

The label instructions for a missed weekly dose differ between agents, and reading the actual prescribing information rather than a summary is worth the ten minutes — the thresholds are specific and the reasoning behind them is stated.

One qualification — this is protocol arithmetic and reported practice, not a recommendation. The compounds in question are not approved for human use when supplied for research.

Read the actual prescribing information for the agent in question. It is short, specific, and more reliable than any summary of it.

What the label says and what the trial protocols permitted are different documents, and the difference is instructive: protocols generally allowed a step to be delayed or reversed for intolerance, and a substantial minority of participants used that provision.

Extending the interval and reducing the dose are not equivalent manoeuvres. Reducing the dose lowers the whole concentration-time curve proportionally. Extending the interval lowers the average but deepens the trough, and for a compound whose effect on appetite tracks concentration, a deep trough is felt.

The part that matters: the maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.

SURMOUNT-4 is the withdrawal trial to read on the maintenance question: after an open-label lead-in, randomised withdrawal produced substantial regain in the placebo arm while continued treatment produced continued loss. It is the cleanest available answer to "what happens if I stop".

The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.

If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.

edited 25 Jun 2026 by meniscus_film — removed a claim I could not source

Stated carefully, for a compound with a seven-day half-life, dose timing is much less consequential than people expect and dose rate is much more consequential.

The argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.

The pharmacokinetics of the acylated agonists are well described: absorption from the subcutaneous depot is slow and rate-limiting, the elimination half-life is approximately one week, and steady state is reached in four to five weeks. Every dosing question in this section follows from those three facts.

I would add that tolerability is not a proxy for benefit. Tolerating a higher dose easily is not evidence that you need one.

Write down in advance what would make you hold a step, because deciding that in the middle of a bad week is not when you are at your most analytical.

Concretely, answering this requires distinguishing the maximum studied dose from the maximum useful dose. The trials established the former. The latter is a per-person question that the trials were not designed to answer.

Where the label ladders differ between agents, the differences track the potency ratio and the tolerability profile rather than anything deeper. It is worth reading the ladders side by side once, because the pattern — small starting dose, four-week steps, a defined maintenance range and a defined maximum — is identical in structure across the class.

SURMOUNT-1 used a twenty-week escalation of tirzepatide in 2.5 mg increments to maintenance doses of 5, 10 and 15 mg weekly, and reported a clear dose-response across those maintenance levels — which is the closest thing to evidence that the top of the ladder does more than the middle.

The limitation of all trial-derived dosing reasoning is that trial populations were selected, monitored and supported in ways that do not resemble anyone reading this.

The short version: four-week steps because that is steady state, and the ladder is about the side effects, not the result.